Rokajax search

Sunday, 3rd July 2022



  • Home
  • Lopez Companies
    • Business and Finance
    • Calendar
    • Promos and Offers
    • Lopez Group Companies
  • HR Updates
    • HR Council
    • Business Excellence
    • Job Opportunities
  • Employee News
    • Message from Lopez
    • Meet the Executive
    • Meet the Team
    • Milestones
    • Spotlight
    • Advocacy
  • Corporate Sustainability
    • ABS-CBN Foundation
    • Sagip Kapamilya
    • OML Climate Change Center
    • Knowledge Channel
    • Lopez Museum
  • Lifestyle
    • Kapamilya Entertainment
    • Power Plant Mall Finds
    • ABS-CBN Publications
    • Food and Recipes
    • Lifelong Wellness
  • Blog
  • Lopez Values
    • 7 Lopez Values
    • The Credo
    • Web Comics
    • Special Feature

All about the vaxx

Twitter

All about the vaxxAll about the vaxxHeres a quick look at the main vaccine brands being used in Vac2Normal and in the Kapamilya Vaccination Program: AstraZeneca, Moderna and Novavax’s Covovax.

OXFORD ASTRAZENECA

Manufacturer/developer: AstraZeneca, University of Oxford (UK)

Countries with EUA: 99 countries including US, UK, Australia, Mexico, Argentina, India, Philippines

Philippine FDA EUA approval: January 28, 2021

Age group covered by FDA EUA approval: 18 years old and above

Technology platform: Viral vector (nonreplicating)

Dose and frequency: 2 doses, 4-12 weeks apart

Vaccine efficacy (VE): 70.4% overall VE against symptomatic COVID-19, 14 days after the second dose

Common adverse events reported in Phase III clinical trials: Injection site pain and tenderness, fatigue, headache, feverishness, myalgia (muscle pain)

Serious adverse events reported in Phase III clinical trials: None reported

 

MODERNA

Manufacturer/developer: Moderna, National Institute of Allergy and Infectious Diseases (US)

Countries with EUA: 49 countries with EUA approval including US, UK, EU, Switzerland, Canada, Australia, Philippines

Philippine FDA EUA approval: May 5, 2021

Age group covered by FDA EUA approval: 18 years old and above

Technology platform: mRNA

Dose and frequency: 2 doses, 28 days apart

Vaccine efficacy (VE): 94.1% overall VE against symptomatic COVID-19, occurring at least 14 days after the second dose; 100% VE against severe COVID-19

Common adverse events reported in Phase III clinical trials: Injection site pain, fatigue, headache myalgia (muscle pain), arthralgia (joint pain), chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site and erythema (skin redness/inflammation) at the injection site

Serious adverse events reported in Phase III clinical trials: Severe allergic reactions, including anaphylaxis

 

COVOVAX

Manufacturer/developer: Serum Institute of India, Novavax (US)

Countries with EUA: No EUA approvals yet

Philippine FDA EUA approval: --

Age group covered by FDA EUA approval: --

Technology platform: Protein subunit

Dose and frequency: 2 doses, 21 days apart

Vaccine efficacy (VE): Awaiting EUA application

Common adverse events reported in Phase III clinical trials: Awaiting EUA application

Serious adverse events reported in Phase III clinical trials: Awaiting EUA application (Source: doh.gov.ph)

 

More Articles from Lopezlink

COVID-19 in PH (June)

Elaine Uy-Casipit and Ginny Monteagudo-Ocampo: Embracing digital and beyond

Elaine Uy-Casipit and Ginny Monteagudo-Ocampo: Embracing digital and beyond

First Balfour achieves ISO 9001:2015 certification

First Balfour achieves ISO 9001:2015 certification

ABS-CBN News partners with over 50 orgs for wider Halalan coverage

ABS-CBN News partners with over 50 orgs for wider Halalan coverage

At EDC, it’s always health and safety first

At EDC, it’s always health and safety first

3 companies reallocate 10K vaccines for Batangas LGUs

3 companies reallocate 10K vaccines for Batangas LGUs

La Mesa to host Malasimbo in 2020

La Mesa to host Malasimbo in 2020

Meet the team of CPI

Meet the team of CPI

Moving forward in a new world

Moving forward in a new world

IWCCO turns over ‘donations from the heart’ to Operation Sagip

IWCCO turns over ‘donations from the heart’ to Operation Sagip

Advocacy of G Eco Tours: helping the helpers

Advocacy of G Eco Tours: helping the helpers

SKYBIZ launches campaign to help jumpstart businesses

SKYBIZ launches campaign to help jumpstart businesses

Management milestones

SKYBIZ enables women entrepreneurs

SKYBIZ enables women entrepreneurs

SKYcable, SKY Fiber continue to operate

SKYcable, SKY Fiber continue to operate

ABS-CBN Publications

‘Pantawid ng Pag-ibig’ concert records 3.7M online views

‘Pantawid ng Pag-ibig’ concert records 3.7M online views

ABS-CBN’s “Pantawid ng Pag-ibig: At Home Together Concert” recorded 3.7 million views during its livestreaming across the network’s digital platforms on March 22.

Subscribe to Lopezlink

Lopez Holdings Corp. All rights reserved



About Us | Copyright | Sitemap | Archive